Business Context and Reporting Period
This Form 8-K, dated February 26, 2026, reports the consummation of a pro rata distribution of Atrium Therapeutics, Inc. (the "Company") common stock by Avidity Biosciences, Inc. ("Avidity"). The Company is a Delaware corporation with its principal executive offices in San Diego, California. The distribution occurred at a ratio of one share of Atrium common stock for every ten shares of Avidity common stock held as of the February 12, 2026 record date.
Key Financial Metrics and Transaction Details
- Shares Distributed: An aggregate of 15,514,966 shares of Atrium common stock were distributed.
- Parent Company Interest: Following the distribution, Avidity no longer owns any equity interest in Atrium Therapeutics.
- Trading Information: Shares are expected to begin trading on February 27, 2026 on The Nasdaq Global Select Market under the symbol "RNA".
- Financial Data: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the Company.
Material Changes and Related Transactions
The primary material change is the separation of Atrium Therapeutics from Avidity Biosciences via the Distribution. Concurrently, the closing of the previously announced acquisition of Avidity by Novartis AG (the "Acquisition") is expected to occur on February 27, 2026, subject to the satisfaction or waiver of customary closing conditions.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Transactions (Distribution and Acquisition). Management cautions that actual results may vary materially due to known and unknown risks. There is no guarantee that the Acquisition will be completed in the expected timetable or at all. The Company does not undertake an obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the commencement of trading for Atrium Therapeutics (RNA) on The Nasdaq Global Select Market on February 27, 2026.
- Confirm the closing of the Novartis AG acquisition of Avidity Biosciences, Inc.
- Review the attached Information Statement (Exhibit 99.1) for detailed business and management information.
- Monitor for any updates regarding the satisfaction or waiver of closing conditions for the Novartis transaction.